Edwards Lifesciences Corp (EW) concluded trading on Wednesday at a closing price of $76.66, with 6.03 million shares of worth about $462.07 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 8.92% during that period and on Wednesday the price saw a gain of about 0.58%. Currently the company’s common shares owned by public are about 586.20M shares, out of which, 574.68M shares are available for trading.
Stock saw a price change of -1.50% in past 5 days and over the past one month there was a price change of 1.48%. Year-to-date (YTD), EW shares are showing a performance of 3.55% which decreased to -12.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $58.93 but also hit the highest price of $95.25 during that period. The average intraday trading volume for Edwards Lifesciences Corp shares is 4.83 million. The stock is currently trading 1.12% above its 20-day simple moving average (SMA20), while that difference is up 4.91% for SMA50 and it goes to 8.29% higher than SMA200.
Edwards Lifesciences Corp (NYSE: EW) currently have 586.20M outstanding shares and institutions hold larger chunk of about 87.92% of that.
The stock has a current market capitalization of $44.97B and its 3Y-monthly beta is at 1.11. PE ratio of stock for trailing 12 months is 51.22, while it has posted earnings per share of $1.50 in the same period. Its PEG reads 5.99 and has Quick Ratio of 3.66 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EW, volatility over the week remained 1.41% while standing at 1.11% over the month.
Analysts are in expectations that Edwards Lifesciences Corp (EW) stock would likely to be making an EPS of 0.62 in the current quarter, while forecast for next quarter EPS is 0.6 and it is 2.75 for next year. For the current quarter EPS, analysts have given the company a lowest target 0.6 which is 0.66 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.7 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 1.63% while it is estimated to increase by 11.48% in next year. EPS is likely to grow at an annualized rate of 8.55% for next 5-years, compared to annual growth of -2.36% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on April 24, 2025 offering an Overweight rating for the stock and assigned a target price of $80 to it. Coverage by Stifel stated Edwards Lifesciences Corp (EW) stock as a Buy in their note to investors on January 30, 2025, suggesting a price target of $90 for the stock. Stock get an Equal-weight rating from Morgan Stanley on October 11, 2024.
